APRIL 27, 2021
Biophytis – Convening of Another Combined General Meeting at a Later Date
APRIL 26, 2021
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
APRIL 13, 2021
Biophytis Identifies False Report Regarding COVA Study
MARCH 22, 2021
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
MARCH 19, 2021
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
MARCH 10, 2021
Biophytis AGM meeting will take place on April 26, 2021
FEBRUARY 26, 2021
Biophytis Reports 2020 Full Year Results
FEBRUARY 17, 2021
Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) following Regulatory Authorities approvals in France and Belgium
February 15, 2021
Biophytis Announces Closing of ADS Offering on Nasdaq Capital Market
February 10, 2021
Biophytis Announces Pricing of $20.1 Million U.S. Initial Public Offering of American Depositary Shares and Approval to List on Nasdaq Capital Market